Comparison of the efficacy of autogenous inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccines with that of commercial vaccines against homologous and heterologous challenges.
about
Pathogenesis and prevention of placental and transplacental porcine reproductive and respiratory syndrome virus infection.Protective humoral immune response induced by an inactivated porcine reproductive and respiratory syndrome virus expressing the hypo-glycosylated glycoprotein 5.Boosting in planta production of antigens derived from the porcine reproductive and respiratory syndrome virus (PRRSV) and subsequent evaluation of their immunogenicity.Different clinical, virological, serological and tissue tropism outcomes of two new and one old Belgian type 1 subtype 1 porcine reproductive and respiratory virus (PRRSV) isolates.Recognition of Highly Diverse Type-1 and -2 Porcine Reproductive and Respiratory Syndrome Viruses (PRRSVs) by T-Lymphocytes Induced in Pigs after Experimental Infection with a Type-2 PRRSV Strain.A Synthetic Porcine Reproductive and Respiratory Syndrome Virus Strain Confers Unprecedented Levels of Heterologous Protection.Safety and early onset of immunity with a novel European porcine reproductive and respiratory syndrome virus vaccine in young piglets.Safety and efficacy of a novel European vaccine for porcine reproductive and respiratory virus in bred gilts.Challenges in Veterinary Vaccine Development and Immunization.Evaluation of Different DNA Vaccines against Porcine Reproductive and Respiratory Syndrome (PRRS) in Pigs.Molecular epidemiology of porcine reproductive and respiratory syndrome viruses isolated from 1991 to 2013 in Taiwan.Comparison of host immune responses to homologous and heterologous type II porcine reproductive and respiratory syndrome virus (PRRSV) challenge in vaccinated and unvaccinated pigs.EMA and EFSA Joint Scientific Opinion on measures to reduce the need to use antimicrobial agents in animal husbandry in the European Union, and the resulting impacts on food safety (RONAFA)Porcine reproductive and respiratory syndrome virus neutralizing antibodies provide in vivo cross-protection to PRRSV1 and PRRSV2 viral challenge.Recent advances in veterinary applications of structural vaccinology.Modified-live PRRSV subtype 1 vaccine UNISTRAIN® PRRS provides a partial clinical and virological protection upon challenge with East European subtype 3 PRRSV strain Lena.Production Losses From an Endemic Animal Disease: Porcine Reproductive and Respiratory Syndrome (PRRS) in Selected Midwest US Sow Farms.Pigs that recover from porcine reproduction and respiratory syndrome virus infection develop cytotoxic CD4+CD8+ and CD4+CD8- T-cells that kill virus infected cells
P2860
Q33613149-40BB1CCA-4F38-4BC1-9C1B-8E09C6D67D45Q34121241-8706F6CA-A18A-4972-965B-3B52C62AD6EBQ35116494-E5C170DB-4B1C-49DD-8887-0982A5D2C433Q35200948-D3DD5AE9-DFBD-42BA-ADDF-1BAC72D3A783Q36178539-C669B942-FC4F-4B33-9306-678CA066C96CQ36281179-B91CBD08-1023-4181-9610-82ACB8B94385Q36811013-7B58B831-EA54-40A5-A0E1-74DA79FD887BQ37315615-170C7165-F683-4461-8BAE-C9A5B75BB223Q38807872-8208EB46-C952-438B-AB89-D0C9FEF2F6F5Q40568255-10A3050D-F41F-4F61-908C-6E6643171742Q40656239-D65CB3F4-5770-4DC9-9D80-866E8D7CC385Q42225595-B054E4F3-0E25-4FBA-8AE9-6421F9158D9DQ47158624-BFF8858A-95C9-4B8E-8470-05A5E722BBB9Q50166841-02F4DF2C-F05B-47B7-802A-718C9B3E1628Q52650429-AE15B27A-76A1-4CE1-89B2-9995FBBFA093Q54406243-41416654-5420-428D-982E-672F5B6DDDA4Q55237121-66B0D1F8-F52C-4DCC-90F4-C22F695B6E1FQ57160272-D879D0A0-809E-494F-9AEF-FD2AAFBCF023
P2860
Comparison of the efficacy of autogenous inactivated Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccines with that of commercial vaccines against homologous and heterologous challenges.
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Comparison of the efficacy of ...... s and heterologous challenges.
@ast
Comparison of the efficacy of ...... s and heterologous challenges.
@en
Comparison of the efficacy of ...... and Respiratory Syndrome Virus
@nl
type
label
Comparison of the efficacy of ...... s and heterologous challenges.
@ast
Comparison of the efficacy of ...... s and heterologous challenges.
@en
Comparison of the efficacy of ...... and Respiratory Syndrome Virus
@nl
prefLabel
Comparison of the efficacy of ...... s and heterologous challenges.
@ast
Comparison of the efficacy of ...... s and heterologous challenges.
@en
Comparison of the efficacy of ...... and Respiratory Syndrome Virus
@nl
P2093
P2860
P356
P1476
Comparison of the efficacy of ...... s and heterologous challenges.
@en
P2093
Jan Van Doorsselaere
Marc F Geldhof
Merijn Vanhee
Uladzimir U Karniychuk
Wander Van Breedam
P2860
P2888
P356
10.1186/1746-6148-8-182
P577
2012-10-03T00:00:00Z
P5875
P6179
1003036130